Supervised pulmonary hypertension exercise rehabilitation (SPHERe): study protocol for a multi-centre randomised controlled trial.
Cardiac rehabilitation
Complex intervention
Pulmonary hypertension
Pulmonary rehabilitation
Randomised controlled trial
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
19 May 2020
19 May 2020
Historique:
received:
08
04
2020
accepted:
11
05
2020
entrez:
21
5
2020
pubmed:
21
5
2020
medline:
17
2
2021
Statut:
epublish
Résumé
Supervised cardio-pulmonary rehabilitation may be safe and beneficial for people with pulmonary hypertension (PH) in groups 1 (pulmonary arterial hypertension) and 4 (chronic thromboembolic disease), particularly as a hospital in-patient. It has not been tested in the most common PH groups; 2 (left heart disease), 3 (lung disease), or 5 (other disorders). Further it has not been evaluated in the UK National Health Service (NHS) out-patient setting, or with long-term follow-up. The aim of this randomised controlled trial (RCT) is to test the clinical and cost-effectiveness of a supervised exercise rehabilitation intervention with psychosocial support compared to best practice usual care for people with PH in the community/outpatient setting. This multi-centre, pragmatic, two-arm RCT with embedded process evaluation aims to recruit 352 clinically stable adults with PH (groups 1-5) and WHO functional class II-IV. Participants will be randomised to either the Supervised Pulmonary Hypertension Exercise Rehabilitation (SPHERe) intervention or control. The SPHERe intervention consists of 1) individual assessment and familiarisation sessions; 2) 8-week, twice-weekly, supervised out-patient exercise training; 3) psychosocial/motivational support and education; 4) guided home exercise plan. The control intervention consists of best practice usual care with a single one-to-one practitioner appointment, and general advice on physical activity. Outcomes will be measured at baseline, 4 months (post-intervention) and 12 months by researchers blinded to treatment allocation. The primary outcome is the incremental shuttle walk test at 4 months. Secondary outcomes include health-related quality of life (HRQoL), time to clinical worsening and health and social care use. A purposive sample of participants (n = 20 intervention and n = 20 control) and practitioners (n = 20) will be interviewed to explore experiences of the trial, outcomes and interventions. The SPHERe study is the first multi-centre clinical RCT to assess the clinical and cost effectiveness of a supervised exercise rehabilitation intervention compared to usual care, delivered in the UK NHS, for people in all PH groups. Results will inform clinicians and commissioners as to whether or not supervised exercise rehabilitation is effective and should be routinely provided for people with PH. ISRCTN no. 10608766, prospectively registered on 18th March 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Supervised cardio-pulmonary rehabilitation may be safe and beneficial for people with pulmonary hypertension (PH) in groups 1 (pulmonary arterial hypertension) and 4 (chronic thromboembolic disease), particularly as a hospital in-patient. It has not been tested in the most common PH groups; 2 (left heart disease), 3 (lung disease), or 5 (other disorders). Further it has not been evaluated in the UK National Health Service (NHS) out-patient setting, or with long-term follow-up. The aim of this randomised controlled trial (RCT) is to test the clinical and cost-effectiveness of a supervised exercise rehabilitation intervention with psychosocial support compared to best practice usual care for people with PH in the community/outpatient setting.
METHODS
METHODS
This multi-centre, pragmatic, two-arm RCT with embedded process evaluation aims to recruit 352 clinically stable adults with PH (groups 1-5) and WHO functional class II-IV. Participants will be randomised to either the Supervised Pulmonary Hypertension Exercise Rehabilitation (SPHERe) intervention or control. The SPHERe intervention consists of 1) individual assessment and familiarisation sessions; 2) 8-week, twice-weekly, supervised out-patient exercise training; 3) psychosocial/motivational support and education; 4) guided home exercise plan. The control intervention consists of best practice usual care with a single one-to-one practitioner appointment, and general advice on physical activity. Outcomes will be measured at baseline, 4 months (post-intervention) and 12 months by researchers blinded to treatment allocation. The primary outcome is the incremental shuttle walk test at 4 months. Secondary outcomes include health-related quality of life (HRQoL), time to clinical worsening and health and social care use. A purposive sample of participants (n = 20 intervention and n = 20 control) and practitioners (n = 20) will be interviewed to explore experiences of the trial, outcomes and interventions.
DISCUSSION
CONCLUSIONS
The SPHERe study is the first multi-centre clinical RCT to assess the clinical and cost effectiveness of a supervised exercise rehabilitation intervention compared to usual care, delivered in the UK NHS, for people in all PH groups. Results will inform clinicians and commissioners as to whether or not supervised exercise rehabilitation is effective and should be routinely provided for people with PH.
TRIAL REGISTRATION
BACKGROUND
ISRCTN no. 10608766, prospectively registered on 18th March 2019.
Identifiants
pubmed: 32429969
doi: 10.1186/s12890-020-01182-y
pii: 10.1186/s12890-020-01182-y
pmc: PMC7236437
doi:
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
143Subventions
Organisme : Department of Health
ID : 17/129/02
Pays : United Kingdom
Organisme : Health Technology Assessment Programme
ID : 17/129/02
Références
BMJ. 2013 Apr 16;346:f2028
pubmed: 23592451
J Heart Lung Transplant. 2017 Aug;36(8):871-879
pubmed: 28579006
BMJ. 2010 Mar 23;340:c332
pubmed: 20332509
Chest. 2013 Nov;144(5):1521-1529
pubmed: 23907471
Circulation. 2006 Sep 26;114(13):1417-31
pubmed: 17000921
Cochrane Database Syst Rev. 2017 Jan 19;1:CD011285
pubmed: 28099988
BMJ. 2013 Jan 08;346:e7586
pubmed: 23303884
BMJ Open. 2013 Nov 15;3(11):e003555
pubmed: 24240140
J Am Coll Cardiol. 2017 Apr 4;69(13):1718-1734
pubmed: 28359519
Adv Exp Med Biol. 2017;1000:153-172
pubmed: 29098621
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
Respirology. 2018 Feb;23(2):148-159
pubmed: 28845582
PLoS One. 2016 Apr 13;11(4):e0147311
pubmed: 27073897
Thorax. 2013 Sep;68 Suppl 2:ii1-30
pubmed: 23880483
Eur Respir J. 2014 Dec;44(6):1428-46
pubmed: 25359355
Qual Life Res. 2006 Feb;15(1):103-15
pubmed: 16411035
Psychol Rev. 1977 Mar;84(2):191-215
pubmed: 847061
Cochrane Database Syst Rev. 2014 Dec 12;(12):CD011273
pubmed: 25503364
BMC Med Res Methodol. 2013 Sep 18;13:117
pubmed: 24047204
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D34-41
pubmed: 24355639
Prog Cardiovasc Dis. 2016 Jul-Aug;59(1):87-94
pubmed: 26569571
Eur Heart J. 2016 Jan 1;37(1):67-119
pubmed: 26320113
Arch Neurol. 1989 Oct;46(10):1121-3
pubmed: 2803071
Cardiol Clin. 2016 Aug;34(3):435-41
pubmed: 27443139
Cochrane Database Syst Rev. 2015 Feb 23;(2):CD003793
pubmed: 25705944
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
BMJ Open Sport Exerc Med. 2018 Oct 16;4(1):e000400
pubmed: 30364456
BMC Cardiovasc Disord. 2017 Sep 6;17(1):239
pubmed: 28874133
Circulation. 2017 Apr 18;135(16):e894-e918
pubmed: 28336790
Heart. 2013 Aug;99(15):1069-71
pubmed: 23403407
BMJ Open Respir Res. 2018 Mar 1;5(1):e000263
pubmed: 29531745
Eur Respir J. 2012 Jul;40(1):84-92
pubmed: 22323570
BMC Med Res Methodol. 2013 Aug 20;13:104
pubmed: 23961782
Respiration. 2016;91(5):359-66
pubmed: 27189373
Respirology. 2017 May;22(4):800-819
pubmed: 28339144
J Clin Med. 2016 Aug 26;5(9):
pubmed: 27571110
Stat Med. 2008 Jul 10;27(15):2850-64
pubmed: 17960589
BMJ. 2018 Mar 14;360:j5492
pubmed: 29540357